-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
Recursion Pharmaceuticals, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2020 to Q2 2024.
- Recursion Pharmaceuticals, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$101M, a 23% decline year-over-year.
- Recursion Pharmaceuticals, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$395M, a 43.7% decline year-over-year.
- Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2023 was -$350M, a 42.5% decline from 2022.
- Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2022 was -$246M, a 34.4% decline from 2021.
- Recursion Pharmaceuticals, Inc. annual Operating Income (Loss) for 2021 was -$183M, a 116% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)